Nature Article 11April 2023 on Oncolytic Viruses mentions UShttps://www.nature.com/articles/s41392-023-01407-6
------------
Oncolytic virotherapy: basic principles, recent advances and future directions
"Among various combination strategies, the prospect of OV combined with immunotherapy is the most promising."
---------------------------------
"Notably, pelareorep combined with atezolizumab and chemotherapy (gemcitabine/nab-paclitaxel) has demonstrated encouraging results as first-line treatment in advanced or metastatic PDAC patients. The trial found that the ORR of patients reached 70%, which was almost three times (25%) the average ORR of the historical control, and the results are amazing. However, the trial did not report data on patient survival, such as median PFS, median OS, etc. The follow-up results deserve further attention. Although the overall efficacy of the three-drug combination is acceptable, its potential side effects also call for vigilance."
------------------------------------